Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.75 USD | +3.05% | +22.06% | -24.92% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.92% | 499M | B- | ||
+10.44% | 106B | B+ | ||
+0.82% | 104B | B+ | ||
+6.72% | 23.25B | B | ||
-13.89% | 22.5B | B+ | ||
-6.64% | 18.7B | A- | ||
-37.26% | 17.95B | A- | ||
-10.98% | 16.99B | B | ||
+8.67% | 14.26B | C+ | ||
+41.08% | 12.76B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TVTX Stock
- Ratings Travere Therapeutics, Inc.